The present invention relates to a pharmaceutical composition comprising in at least one pharmaceutically acceptable support or vehicle a combination of (3S 3S ) 4 4 disulfanediylbis(3 aminobutane 1 sulfonic acid) or a pharmaceutically acceptable salt or solvate thereof and a second active ingredient selected from the group consisting of angiotensin I converting enzyme inhibitors and angiotensin II receptor type I antagonists. Said composition isparticularly useful for the treatment of hypertension and related diseases and conditions.